glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
glipizide
RxCUI: 861736
What the CMS Formulary Data Shows for glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
Per the CMS 2026 Part D formulary file, glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet (RxNorm concept RXCUI 861736, generic name glipizide) appears on 328 distinct formulary files spanning 5,059 Medicare Part D plan offerings - 99.8% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.3.
Real-world access to glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 82.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,178,840 Part D beneficiaries filled glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $53,145,778 and an average per-beneficiary annual cost of $45.08. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 328
- Plans covering
- 5,059
- Coverage rate
- 99.8%
- Tier range
- Tier 1 – Tier 6
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 82.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,178,840
- Total spending
- $53,145,778
- Avg per beneficiary
- $45.08
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T1 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T1 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet covered by Medicare Part D?
Yes, glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet is covered by 5,059 Medicare Part D plans (99.8% of all Part D formularies).
What tier is glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet on Medicare Part D plans?
glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet averages Tier 2.3 across Part D plans, ranging from Tier 1 to Tier 6.
Does glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet. Step therapy: 0%. Quantity limits: 82.3%.
How much does Medicare spend on glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet?
In 2023, total Medicare Part D spending on glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet was $53,145,778, covering 1,178,840 beneficiaries. The average spend per beneficiary was $45.08.
Read our methodology - how this data is sourced, computed, and verified.